"With this agreement now in place, Angiotech expects that the resources required to defend and enforce our intellectual property should decrease," said Dr. William Hunter, president and CEO of Angiotech.

At the time of the settlement, there was ongoing litigation in three jurisdictions: the UK, the Netherlands and Australia.